Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy: An Exploratory Analysis of Treatment Effect in Male and Female Patients
Puntos clave
The study aims to evaluate the effectiveness of eplontersen in improving outcomes for patients with hereditary transthyretin amyloidosis with neuropathy, irrespective of sex.
Exploratory analysis of treatment effects of eplontersen versus placebo
Assessment of neuropathy impairment and quality of life measures
Included both male and female patients, considering those with cardiomyopathy
Eplontersen halted neuropathy impairment in patients
Improvement in quality of life was observed in both sexes
Effectiveness was similar between male and female patients
Resumen
Eplontersen halted neuropathy impairment and improved quality of life versus placebo to a similar degree in both male and female patients with ATTRv-PN, including those with cardiomyopathy. These findings support the use of eplontersen as an effective treatment for ATTRv-PN regardless of sex.
Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy: An Exploratory Analysis of Treatment Effect in Male and Female Patients | Synapse
Cite This Study
Waddington‐Cruz et al. (Mon,) studied this question.